

Webinar Recording: Incubating and Launching New Life Science Companies

March 09, 2021 | Webinar | By **Lewis J. Geffen**

VIEWPOINT TOPICS

- Life Sciences
-

RELATED PRACTICES

- Venture Capital & Emerging Companies
-

RELATED INDUSTRIES

- Life Sciences
- Impact Capital & Social Innovation

Image not found or type unknown

This 90-minute webinar explored the processes, considerations, and other factors behind the incubation and launch of new companies by some of today's leading venture capital firms. Our panelists addressed these key questions and topics:

- What are common sources of ideas for new companies and how do VC business models facilitate and measure the progress and de-risking of translational science?
- How do venture firms approach financing a new entity and how do they balance capital at risk and value capture with syndication and/or non-dilutive funding from partnerships?
- What are venture firms' views on founder equity for inventors, for initial key team members, and for their own firms in their capacity as new company founders?
- What are key steps to creating an ideal initial management team?

Panelists included:

- Nessian Bermingham, PhD, Serial entrepreneur and investor; currently *President & CEO*, Triplet Therapeutics, *Executive Chairman*, Korro Bio
- Nathaniel Brooks Horwitz, *Principal*, Venture Team, RA Capital Management; board member of multiple companies
- Deborah Palestrant, PhD, *Partner, Head of 4:59*, 5AM Ventures

Their full bios can be found [here](#).

Authors



Lewis J. Geffen, Member

Lewis J. Geffen is a corporate and licensing attorney at Mintz who helps companies manage strategic issues and complex transactions. Lewis provides financing and licensing guidance to biotechnology, pharmaceutical, medical device, and MedTech companies.